Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome
Cardiorenal syndrome encompasses a spectrum of disorders involving heart and kidney dysfunction, and sharing common risk factors, such as hypertension and diabetes. Clinical studies have shown that patients with and without diabetes may benefit from using sodium-glucose cotransporter 2 inhibitors to...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | 英语 |
| 出版: |
2023
|
| 在線閱讀: | https://doi.org/10.1016/j.phrs.2023.106659 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|